Business Operations:

Sector: Healthcare
Industry: Healthcare Plans

Humana Inc. provides medical and specialty insurance products in the United States. It operates in two segments, Insurance and CenterWell. The Insurance segment offers individual Medicare Advantage products, including health insurance benefits, including wellness programs, chronic care management, and care coordination; individual Medicare stand-alone prescription drug products (PDP); group Medicare advantage and Medicare stand-alone PDP; Medicare supplements; specialty and ancillary insurance comprising dental, vision, life and disability; and administrative services to arrange health care services for active-duty and retired military personnel and dependents, as well as pharmacy benefit managers. Its CenterWell segment operates full-service, value-based senior focused primary care centers under the Conviva Senior Primary Care and CenterWell Senior Primary Care brands; a management services organization; CenterWell Home Health, a home health provider; and OneHome, which manages post-acute patient needs, as well as provides pharmacy and hospice solutions. The company was formerly known as Extendicare Inc. and changed its name to Humana Inc. in April 1974. Humana Inc. was founded in 1961 and is headquartered in Louisville, Kentucky.

Revenue projections:

HUM's revenue projections indicate a decrease from the prior year, which may make investors hesitant. A revenue decline could harm the company's bottom line, prompting investors to be more careful, as lower earnings often signal potential issues with profitability and future performance.

Financial Ratios:

currentRatio	1.74200
forwardPE	24.60043
debtToEquity	76.48500
earningsGrowth	0.27100
revenueGrowth	0.26200
grossMargins	0.13653
operatingMargins	0.03465
trailingEps	10.58000
forwardEps	17.08832

A current ratio of 1.742 for Humana Inc. implies that the company has ample liquidity to meet its short-term debts. Humana Inc.'s cash reserves and current assets should easily cover these obligations, highlighting its financial stability and ability to manage short-term liabilities.
Humana Inc.'s Forward PE is at a healthy level, meaning the stock price is aligned favorably with earnings. This suggests that the stock isn't overpriced, providing room for growth and making it an appealing option for investors looking to capitalize on potential future gains.
HUM's positive earnings and revenue growth signal the company's business is on track for further expansion. These strong financial trends suggest that HUM will continue to grow its operations, driven by increasing profits and revenue.
HUM's forward EPS is higher than its trailing EPS, suggesting the company is expected to see an increase in profitability this year. This points to positive growth, indicating that HUM is projected to improve its financial performance compared to the previous year.

Price projections:

HUM's price projections have been revised upward over time, suggesting that analysts are becoming more confident in the company's future. This trend points to increased optimism about HUM's ability to grow.

Insider Transactions:

HUM had 1 buy transactions while market price was at 181.16000366210938 per share.During the period under consideration, no buy transactions took place.HUM's current price levels are marked by increased selling, which could indicate further price drops. If this selling trend persists, the stock may continue to decline as investor confidence weakens.

Recommendation changes over time:

Analysts are favoring HUM with a buy bias, highlighting the stock's potential as a solid investment. This recommendation might drive more investors to consider HUM as a secure and profitable option for their money, contributing to a broader positive sentiment in the market.